Structuring a fecal microbiota transplantation center in a university hospital in Brazil

• Autor(a) principal: Daniel Antônio de Albuquerque Terra
• Data de Publicação: 2020
• Outros Autores: Eduardo Garcia Vilela, Rodrigo Otávio Silveira Silva, Laiane Alves Leão, Karine Sampaio Lima, Raissa Iglesias Fernandes Ângelo Passos, Amanda Nadia Diniz, Luiz Gonzaga Vaz Coelho
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: https://doi.org/10.1590/S0004-2803.202000000-79; http://hdl.handle.net/1843/51785; https://orcid.org/0000-0001-9691-6512; https://orcid.org/0000-0002-5443-7553; https://orcid.org/0000-0003-0074-2488; https://orcid.org/0000-0001-6547-3798; https://orcid.org/0000-0001-8897-3410; https://orcid.org/0000-0003-0705-5568; https://orcid.org/0000-0002-5287-5779; https://orcid.org/0000-0002-8721-7696
• topic: Fecal microbiota transplantation; Clostridium infections; Microbiota; Gastrointestinal microbiome; Diarrhea; Feces; Transplante de microbiota fecal; Infecções por clostridium; Microbiota; Microbioma gastrointestinal; Diarreia; Fezes

Background: Fecal microbiota transplantation (FMT) is an important therapeutic option for recurrent or refractory Clostridioides difficile infection, being a safe and effective method. Initial results suggest that FMT also plays an important role in other conditions whose pathogenesis involves alteration of the intestinal microbiota. However, its systematized use is not widespread, especially in Brazil. In the last decade, multiple reports and several cases emerged using different protocols for FMT, without standardization of methods and with variable response rates. In Brazil, few isolated cases of FMT have been reported without the implantation of a Fecal Microbiota Transplantation Center (FMTC). Objective: The main objective of this study is to describe the process of implanting a FMTC with a stool bank, in a Brazilian university hospital for treatment of recurrent and refractory C. difficile infection. Methods: The center was structured within the criteria required by international organizations such as the Food and Drug Administration, the European Fecal Microbiota Transplant Group and in line with national epidemiological and regulatory aspects. Results: A whole platform involved in structuring a transplant center with stool bank was established. The criteria for donor selection, processing and storage of samples, handling of recipients before and after the procedure, routes of administration, short and long-term follow-up of transplant patients were determined. Donor selection was conducted in three stages: pre-screening, clinical evaluation and laboratory screening. Most of the candidates were excluded in the first (75.4%) and second stage (72.7%). The main clinical exclusion criteria were: recent acute diarrhea, overweight (body mass index ≥25 kg/m2) and chronic gastrointestinal disorders. Four of the 134 candidates were selected after full screening, with a donor detection rate of 3%. Conclusion: The implantation of a transplant center, unprecedented in our country, allows the access of patients with recurrent or refractory C. difficile infection to innovative, safe treatment, with a high success rate and little available in Brazil. Proper selection of qualified donors is vital in the process of implementing a FMTC. The rigorous clinical evaluation of donors allowed the rational use of resources. A transplant center enables treatment on demand, on a larger scale, less personalized, with more security and traceability. This protocol provides subsidies for conducting FMT in emerging countries.